Ustekinumab treatment in patients with moderate-to-severe psoriasis who are non-responders to etanercept: Results from a Phase 3 clinical trial (Abstract P3357)
Authors: C. E. M. Griffiths, University of Manchester, United Kingdom; A. Menter, Baylor University Medical Center, Dallas, TX; B. Strober, New York University School of Medicine, New York, NY; N. Yeilding, Centocor Research & Development, Malvern, PA
Efficacy and safety of infliximab therapy in plaque psoriasis patients previously treated with etanercept: Analysis of PSUNRISE (Abstract P3341)Authors: A.B. Gottlieb, Tufts Medical Center, Boston, MA; J. Wang, Johnson & Johnson Pharmaceutical Research & Development, Horsham, PA; M. Chevrier, Centocor Ortho Biotech Services, Horsham, PA; R. Kalb, SUNY at Buffalo School of Medicine, Buffalo, NY
Electronic poster exhibit viewing stations will be open during the course of the meeting at the Miami Beach Convention Center in Hall D.
SOURCE Centocor Ortho Biotech Inc.